NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
May 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
MS CONTIN (morphine sulfate) by Purdue Pharma is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1987.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MS CONTIN is an extended-release oral tablet formulation of morphine sulfate, a full mu-opioid receptor agonist indicated for moderate to severe chronic pain. It provides sustained analgesia through continuous opioid receptor activation with no ceiling effect, allowing dose titration to patient need. The mechanism involves central nervous system opioid receptor engagement in the brain and spinal cord.
$0.001BPart D
LOE ApproachingProduct is in late-stage lifecycle with minimal Part D claims (1,166 in 2023), signaling declining market presence and likely smaller team focus on retention rather than expansion.
Mechanism of Action
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Started Aug 2010
33 enrolled
Narcotic AbuseOpioid-related DisordersAnalgesia+1 more
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Started Mar 2007
32 enrolled
Healthy
Worked on MS CONTIN at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.